×

Deadline on December 9, 2013 in Lawsuit for Investors in Ariad Pharmaceuticals, Inc. (ARIA) Shares Announced by Shareholders Foundation

SF logo

SAN DIEGO, Nov. 19, 2013 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a deadline to get actively involved is coming up on December 9, 2013 in the lawsuit filed on behalf of certain investors in shares Ariad Pharmaceuticals, Inc. (ARIA) over alleged Securities Laws Violations by Ariad Pharmaceuticals, Inc. in connection with certain statements made regarding its leukemia drug Iclusig.

If you purchased a significant amount of shares of Ariad Pharmaceuticals, Inc. (ARIA) between December 12, 2011 and October 8, 2013, and / or if you purchased ARIA shares prior to 2012 and currently hold any of those shares, you have certain options and you should contact the Shareholders Foundation, Inc. by e-mail at mail@shareholdersfoundation.com or call +1 (858) 779-1554.

The plaintiff alleges that between December 12, 2011 and October 8, 2013 the defendants represented that Ariad Pharmaceuticals; leukemia drug Iclusig (ponatinib), based on its clinical data from its pivotal PACE trial of Iclusig, was safe and effective, without serious adverse events such as serious arterial thrombotic and cardiovascular events.

On October 9, 2013, Ariad Pharmaceuticals, Inc. announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig and actions that it is taking following consultations with the FDA. Ariad Pharmaceuticals, Inc said it was halting all enrollments in Iclusig clinical trials and that the FDA had also placed a partial hold on the trials due to the arterial thrombosis occurring in Iclusig-treated patients. The Company also advised current patients of the drug to lower their dosage.

The plaintiff alleges that it was then when Ariad Pharmaceuticals revealed that the drug was shown to cause a higher rate of blood clots and heart-related side effects than previously disclosed.

Shares of Ariad Pharmaceuticals, Inc. dropped from almost $23 per share in September 2013 to $2.20 in late October 2013.

The plaintiff seeks to recover damages on behalf of all purchasers of Ariad Pharmaceuticals, Inc. stock between December 12, 2011 and October 8, 2013.

Those who purchased shares of Ariad Pharmaceuticals, Inc. have certain options and should contact the Shareholders Foundation, Inc. by e-mail at mail@shareholdersfoundation.com or call +1 (858) 779-1554.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT: Shareholders Foundation, Inc. Trevor Allen +1 (858) 779-1554 mail@shareholdersfoundation.com 3111 Camino Del Rio North Suite 423 San Diego, CA 92108

Source:Shareholders Foundation, Inc.